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Background: H-rev107 is a member of the HREV107 type II tumor suppressor gene family which includes H-REV107,
RIG1, and HRASLS. H-REV107 has been shown to express at high levels in differentiated tissues of post-meiotic
testicular germ cells. Prostaglandin D2 (PGD2) is conjectured to induce SRY-related high-mobility group box 9 (SOX9)
expression and subsequent Sertoli cell differentiation. To date, the function of H-rev107 in differentiated testicular
cells has not been well defined.
Results: In the study, we found that H-rev107 was co-localized with prostaglandin D2 synthase (PTGDS) and
enhanced the activity of PTGDS, resulting in increase of PGD2 production in testis cells. Furthermore, when
H-rev107 was expressed in human NT2/D1 testicular cancer cells, cell migration and invasion were inhibited. Also,
silencing of PTGDS would reduce H-rev107-mediated increase in PGD2, cAMP, and SOX9. Silencing of PTGDS or
SOX9 also alleviated H-rev107-mediated suppression of cell migration and invasion.
Conclusions: These results revealed that H-rev107, through PTGDS, suppressed cell migration and invasion. Our
data suggest that the PGD2-cAMP-SOX9 signal pathway might play an important role in H-rev107-mediated cancer
cell invasion in testes.
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HREV107 type II tumor suppressorBackground
H-rev107 [1], also called HRASLS3 [2] or PLA2G16 [3],
is a member of the HREV107 type II tumor suppres-
sor gene family, which includes H-REV107, retinoid-
inducible gene 1 (RIG1) [4], HRASLS2 [5,6], HRLP5 [7],
and HRASLS [8]. The protein in this family contains an
NC domain, with unknown function at the N-terminus,
and a hydrophobic membrane-anchoring domain at the
C-terminus [9,10]. The family proteins exhibit activities
that regulate cellular growth, differentiation, and apop-
tosis, and the membrane-anchoring domain is indispen-
sable for this activity [11-14].* Correspondence: jiang.shunyuan@gmail.com; afu2215@gmail.com
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reproduction in any medium, provided the orHuman H-REV107 and RIG1 have been shown to be
involved in the regulation of cellular growth, apoptosis,
and differentiation. RIG1 is expressed in highly diffe-
rentiated tissue derived from skin and colon [13,15,16].
H-REV107 is expressed at high levels in differentiated
tissues of post-meiotic testicular germ cells but not in
testicular germ cell tumors [17]. Both genes are ex-
pressed in normal tissues in a tissue-specific manner
and are downregulated in various cancer tissues [15-18].
These proteins exhibit growth-suppressive activities when
ectopically expressed in various types of cancer cells and
RAS-transformed fibroblasts [6,8,11,13,19-22]. In addi-
tion, terminal differentiation of keratinocytes has been ob-
served in cells with induced RIG1 expression [13,23].
Therefore, the HREV107 protein family might play an im-
portant role in the regulation of cell growth and differen-
tiation in both normal and cancer cells.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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metabolizing, and enhancing transglutaminase activities
among the HREV107 protein family. Murine H-rev107
was first isolated from revertants of HRAS-transformed
fibroblasts [19]. Also, H-REV107 and HRASLS were
shown to inhibit the RAS-mediated transformation of fi-
broblasts [8,20]. Similar inhibition of the RAS signal
pathways has been observed in HRASLS2-expressing [6]
or RIG1-expressing cervical and gastric cancer cells [21].
The results of our studies further demonstrated a
downregulation of activated RAS and total RAS by RIG1
through the post-translational mechanism [11,24]. In
addition to the inhibition of RAS, the HREV107 family
proteins are phospholipid-metabolizing enzymes. H-
REV107 catalyzes the efficient release of free fatty acids
and lysophospholipid from phosphatidylcholine, indica-
ting that it acts as phospholipase A [3]. Also, different
HREV107 family members catalyze particular phosphati-
dylcholines or phosphatidylethanolamines [5,7]. In kera-
tinocytes, RIG1 has been shown to stimulate cellular
differentiation which is mediated by activating type I tis-
sue transglutaminase [13,23]. These results suggest that
RIG1, HRASLS2, and H-REV107 can regulate cellular
differentiation in various tissues through different down-
stream signal pathways.
Prostaglandin D2 (PGD2), which is synthesized by
prostaglandin D2 synthase (PTGDS) in many organs,
has been implicated as a signaling molecule in the medi-
ation or regulation of various biological processes. PGD2
is expressed in male mice in the early stages of gona-
dogenesis [25]. Also, PGD2 is shown to contribute to
SRY-related high-mobility group box 9 (SOX9) nucleus
translocation, which is a critical step of the Sry-initiated
testis-determining cascade [26]. The expression of PTGDS
is expressed in the cellular lineage that gives rise to the
Sertoli cells [27], and the Sertoli cells express PTGDS only
during the VI-VIII stages of the spermatogenic cycle, im-
mediately after spermiation [28]. The studies support the
role of the PGD2/ PTGDS signaling pathway in the regu-
lation of testis tissue differentiation.
The transcriptional factor SOX9 is involved in cell dif-
ferentiation, growth and invasion. SOX9 is a master
regulator of Sertoli cell differentiation during testis de-
velopment and is the crucial gene to determine sex
[26,29,30]. SOX9 also plays a role in osteochodrogenenic
differentiation [31]. SOX9 expression is upregulated by
PGD2, and ectopic SOX9 expression has been shown to
suppress growth of ovarian cancer and melanoma cells
in vitro and/or in vivo [32]. However, both aberrant
SOX9 expression in carcinoma tissues and elevated SOX9
expression are correlated to disease progression and poor
prognosis for hepatocellular carcinoma, gastric cancer and
prostate cancer [33-35]. SOX9 protein levels are elevated
in invasive human uroepithelial carcinoma tissues, whichare induced by the activation of epidermal growth factor
receptor [34]. Therefore, biological activities of SOX9 ap-
pear to be target site specific.
Although high levels of H-REV107 expression in dif-
ferentiated testes suggest a role of H-REV107 in tissue
differentiation, the genuine signaling pathway involved
in the H-REV107-mediated cell differentiation of testes
remains poorly understood. Our recent study revealed
that RIG1 interacted with PTGDS and stimulated PTGDS
activity in human testicular NT2/D1 cells [36]. RIG1 is
expressed in the human species only, whereas H-REV107
is expressed in both human and murine and exhibits high
expression levels in human testes [17]. Since H-rev107
and RIG1 belong to the same protein family, we pos-
tulated that the binding of RIG1 to PTGDS might exist
between H-rev107 and PTGDS. The present results con-
firmed the binding between H-rev107 and PTGDS, and
demonstrated that the H-rev107-mediated suppression of
cell invasion was mediated through the enhancement of
PTGDS activity in the murine in testes. Our results
suggest that the PGD2 pathway might play an important
role in the regulation of H-REV107-mediated testis cell
differentiation.
Methods
Construction of expression vectors
The H-rev107 and PTGDS cDNA fragments were am-
plified from mouse TM4 testis cancer cells (Bioresource
Collection and Research Center [BCRC], Hsinchu,
Taiwan) using H-rev107-specific primers (sense, 5’-
TCCTCGAGCTATGCTAGCACCCATACCAGAACCC-
3’ and antisense, 5’-TCGGATCCTTGCTTCTGTTTC
TTGTTTCTGGAGAGCATG-3’) and PTGDS-specific
primers (sense, 5’-TCAAGCTTCGATGGCTGCTCTT
CGCATGCTGTG-3’ and antisense, 5’- TCGGATCCG
CTCTTGAATGCACTTATCCGGTTGG -3’). To gene-
rate pH-rev107-myc and pDsRed-H-rev107, the ampli-
fied H-rev107 cDNA fragment was digested with XhoI
and BamHI and then subcloned in-frame into the
multicloning site of the pcDNA3.1-myc-his A expression
vector (Invitrogen, Carlsbad, CA, USA) or pDsRed-C1
(Clontech Laboratories, Inc, Palo Alto, CA, USA). To
generate pPTGDS-Flag and pEGFP-PTGDS, the am-
plified PTGDS cDNA fragment that had been diges-
ted with HindIII-BamHI was cloned in-frame into the
pPCR3.1-Flag (Dr. Yi-Ling Lin, Institute of Biomedical
Science, Academia Sinica, Taipei, Taiwan) and pEGFP-
C1 (Clontech Laboratories). The cDNA sequences of fu-
sion proteins were confirmed by DNA sequencing.
Immunohistochemical analysis
Testes tissue sections from Balb/c mice were depara-
ffinized with trilogy (Cell Marque, Rocklin, CA, USA)
and rehydrated in a graded series of ethanol. To retrieve
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DAKO Chem-Mate™ solution (DAKO Co., Carpinteria,
CA, USA) containing 0.05% Nonidet P-40. Endogenous
peroxidase activity was blocked by incubation in 3%
hydrogen peroxide for 10 min. The sections were then
incubated at room temperature for 2 h in H-REV107
(Biorbyt, Cambridge, Cambridgeshire, UK), PTGDS (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), or control
rabbit IgG antibody (Santa Cruz Biotechnology) diluted at
1:1000, 1:200, or 1:400 respectively in DAKO antibody
diluent. The DAKO LSAB® 2 Peroxidase kit was used to
stain protein expression in tissue sections. Sections were
incubated with 3-3’-diaminobenzidine chromogen solution
(DAKO Co) for 5 min to reveal the peroxidase complex. Fi-
nally, sections were lightly counterstained with Mayer’s
hematoxylin (Merck, Darmstadt, Germany) and mounted
with DPX mounting medium (Schrlau, Spain). Our study
had been reviewed and approved by the Buddhist Tzu Chi
General Hospital-Taipei Branch Institutional Animal Care
and Use Committee.
Cell culture and transfection
Mouse TM3 mouse Leydig and TM4 mouse Sertoli cells
(BCRC) were maintained in a growth medium consisting
of a 1:1 mixture of Ham’s F12 medium and Dulbecco's
Modified Essential Medium (DMEM) supplemented
with 4.5 g/L glucose, 2.5 mM L-glutamine, 0.5 mM
sodium pyruvate, 1.2 g/L sodium bicarbonate, 15 mM
HEPES, 5% horse serum, and 2.5% fetal bovine serum
(FBS). Human NT2/D1 teratocarcinoma cancer cells
were maintained in DMEM supplemented with 25 mM
HEPES, 26 mM NaHCO3, 2 mM L-glutamine, penicillin
(100 units/mL), streptomycin (100 μg/mL), and 10% FBS
at 37°C in 5% CO2. Cells plated in culture dishes were
transfected with the expression vectors using liposome-
mediated transfection. Plasmids and lipofectamine 2000
(Gibco BRL, Gaithersburg, MD, USA) were diluted in
Opti-MEM medium and then mixed with plasmids at
room temperature for 15 min. The DNA–lipofectamine
complexes were then added to cells for 5 h at 37°C. Cells
were refreshed with complete medium for 24 h at 37°C
for further analysis.
Immunoprecipitation and Western blotting
Cells were lysed in IP lysis buffer (20 mM Tris-HCl
at pH 7.5, 100 mM NaCl, 1% Nonidet P40, 100 μM
Na3VO4, 50 mM NaF, and 30 mM sodium pyrophos-
phate) containing 1× complete protease inhibitor cocktail
(EDTA-free) (Roche Diagnostics, Mannheim, Germany).
Cell lysates containing 500 μg of protein were first incu-
bated first with 3.2 μg of anti-myc (Invitrogen) or 1 μg of
anti-Flag-M2 (Sigma, St. Louis, MO, USA) monoclo-
nal antibody for 2 h at 4°C and then incubated with
20 μL of protein G plus /protein A agarose (Calbiochem,Cambridge, MA, USA) at 4°C for 2 h. Immunoprecipi-
tated complexes were washed three times with IP lysis
buffer and then analyzed by Western blotting using an
anti-myc or anti-Flag antibody. For Western blotting, pro-
teins (20–50 μg) were separated on 12% polyacrylamide
gels and transferred to polyvinylidene difluoride mem-
branes. After blocking, membranes were incubated with
anti-myc, anti-Flag, anti-PTGDS (Abcam, Cambridge,
UK), anti-phospho-SOX9 (Abcam), anti-SOX9 (Abcam),
anti-E-cadherin (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-vimentin (Santa Cruz Biotechnology), or
anti-actin (Sigma) antibody for 12 h at 4°C and then incu-
bated with horseradish peroxidase-conjugated goat anti-
mouse or anti-rabbit antibody at room temperature for
1 h. An ECL kit (Amersham, Bucks,UK) was used to de-
tect the substrate reaction.
Confocal and immunofluorescent analysis
TM4 cells (1 × 105) were plated on poly-L-lysine-coated
coverslips in 35-mm dishes in growth medium. Cells
were then transfected with 500 ng of DsRed-H-rev107
along with 500 ng pEGFP-PTGDS expression vector for
18 h. The cells were washed, fixed with 4% paraformalde-
hyde, stained with 1 μg/mL 4’6-diamidino-2-phenylindole
(DAPI), and then analyzed with a Leica TCS SP5 scanner
(Leica, Bensheim, Germany). The fluorescent images were
then processed with Image-Pro Plus 5.1 image analysis
software.
Measurement of PGD2 and cAMP levels
Cells were cultured onto 6-well plates overnight and
then transfected with 500 ng of pPTGDS-Flag along
with 500 ng of pH-rev107-myc, or control vector in
complete medium for 5 h. Cells were incubated in
complete medium supplemented with 1 mM Br-cAMP
or ethanol vehicle for 18 h. Alternatively, cells were
washed and then incubated with 1 μg/mL arachidonic
acid (AA, Sigma) for 1 h or PGD2 (500 ng/mL) for
30 min immediately before harvest. After washing twice
with PBS, cells were lysed with 0.1 N HCl for 20 min,
scraped, and collected by centrifugation. Levels of PGD2
or cAMP in the supernatants were determined using
a prostaglandin D2 express or cyclic AMP EIA kit
(Cayman Chemical, Ann Arbor, MI, USA) according to
the manufacturer's instructions.
Cell migration and invasion assay
For cell migration assay, NT2/D1 cells (2 × 104) were ad-
ded to the upper polycarbonate membrane insert (8 μm
pore size; Falcon, Becton, Dickinson and Company,
Franklin Lakes, NJ, USA) of the cell migration assay kit
in a 24-well plate. In the lower well, seven hundred μL
of DMEM supplemented with 20% FBS was used as
chemoattractant. After 24 h of incubation, cells were
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then stained for 30 min at room temperature with a
50 μg/mL solution of propidium iodide (Sigma).
Polycarbonate-membrane inserts coated with 30 μg
Matrigel (BD) were used for cell invasion assays. NT2/
D1 cells (2 × 104), suspended in DMEM medium con-
taining 10% NuSerum (BD), were seeded in the mem-
brane insert. Seven hundred μL of serum-containing
medium supplemented with PGD2 (500 ng/mL) or etha-
nol vehicle was placed in the lower chambers, with the
medium changed daily for 72 h at 37°C. Cells were fixed
and stained for propidium iodide. The number of cells
on each membrane was counted under a microscope at
a magnification of 40×. Experiments were performed at
least twice, and each sample was assayed in triplicate.
Viruses and transduction
LacZ, PTGDS, and SOX9-shRNA-containing lentiviral
vectors were obtained from the National RNAi Core
Facility (Academia Sinica, Taiwan) and prepared in ac-
cordance with standard protocols. Cells were infected
with lentivirus (multiplicity of infection 5) in medium
containing polybrene (8 μg/mL). Two PTGDS shRNAs
targeted to nucleotides 540 to 560 (5’-CAGGGCTGA
GTTAAAGGAGAA-3’) and 625 to 645 (5’-GATAAGT
GCATGACGGAACAA-3’) were synthesized based on
Genbank accession NM_000954. Two SOX9 shRNAs
targeted to nucleotides 1761 to 1781(5’-GATAAGTGC
ATGACGGAACAA-3’) and 3680 to 3700 (5’-GCATC
CTTCAATTTCTGTATA-3’) were synthesized based on
Genbank accession NM_000346.
Rac activation assays
Cells grown to 80% confluence in 10-cm culture dishes
were first transfected with 5 μg H-rev107 or control ex-
pression vector and then incubated with 500 ng/mL of
PGD2 or ethanol vehicle for 24 h. Cells were serum
starved for 12 h and then stimulated with 50 ng/mL epi-
dermal growth factor (EGF, Sigma) for 5 min at 37°C.
Rac1 activity was assessed using the Rac1 activation
assay kit (Millipore, Temecula, CA, USA). Briefly, cells
were washed twice with ice-cold PBS and then lysed in
0.5 mL MLB buffer (25 mM HEPES, pH 7.5, 150 mM
NaCl, 1% Igepal CA-630, 10 mM MgCl2, 1 mM EDTA,
and 10% glycerol) containing protease inhibitors and
phosphatase inhibitors. Cellular lysates containing 300 μg
protein were then incubated with 10 μL of the PAK-1
PBD agarose bound with glutathione S-transferase fusion
protein corresponding to the human p21 binding domain
(PBD, residues 67–150) of human PAK-1 at 4°C for 1 h.
After washing three times with MLB containing protease
and phosphatase inhibitors, presence of the activated Rac1
(Rac1-GTP) was detected by Western blotting using an
anti-Rac1 monoclonal antibody (Millipore).Results
Expression of H-rev107 and PTGDS in mouse testes
To analyze the expression of H-rev107 and PTGDS
proteins in the testis of Balb/c mice, we performed
an immunohistochemical analysis. Strong H-rev107 ex-
pression was detected in spermatids, and no H-rev107
expression was observed in spermatogonia and sperma-
tocytes (Figure 1A). Localization of H-rev107 protein
was similar to H-REV107 RNA detected in human testis
[17]. Similarly, positive PTGDS staining was observed
only in spermatids (Figure 1A). Therefore, H-rev107 and
PTGDS were both expressed in the terminally differenti-
ated testis tissues. No staining was observed in tissues
incubated with rabbit control IgG. The expression of
H-rev107 and PTGDS was also confirmed by Western
blotting in testis cell extracts prepared from three mice
(Figure 1B).
H-rev107 associates and co-localizes with PTGDS
RIG1 can interact with PTGDS [36]. Whether H-rev107
is associated with PTGDS was evaluated. Myc-tagged
H-rev107 or Flag-tagged PTGDS fusion proteins with
expected molecular weights of 22.7 and 23.9 kDa, res-
pectively, were detected in cytosol extracts prepared
from transfected TM3 and TM4 cells (data not shown).
We further performed immunoprecipitation using anti-
myc antibody specific to the myc epitope of the H-
rev107 fusion protein in lysates of PTGDS-Flag and
H-rev107-Myc co-transfected TM4 cells. In Figure 2A,
the left panel shows that PTGDS coprecipitated with
H-rev107 in TM4 cell lysates. Similarly, H-rev107 was
observed on immunoblots from PTGDS co-transfected
immunoprecipitates (Figure 2A, right panel). A similar
interaction between H-rev107 and PTGDS was observed
in TM3 cells (data not shown). We next verified the co-
localization between H-rev107 and PTGDS within cells.
DsRed-H-rev107 and EGFP-PTGDS expression vectors
were co-transfected into TM4 cells for 18 h. Both DsRed-
H-rev107 and EGFP-PTGDS were expressed in cytoplasm
with preferential localization at the peri-nuclear region
(Figure 2B), and most of the DsRed-H-rev107 and EGFP-
PTGDS proteins were co-localized (yellow) in co-trans-
fected cells (Figure 2B and Additional file 1: Figure S1).
H-rev107 enhances PTGDS activity in human NT2/D1
testis cancer cells
The PGD2-SOX9 pathway has been well-studied in hu-
man NT2/D1 teratocarcinoma cells [26]. To examine
the effect of H-rev107 on PTGDS activity, NT2/D1 cells
were co-transfected with the PTGDS expression vector
and either H-rev107 or a control vector for 24 h. AA
treatment significantly increased PGD2 levels by 52%
in control transfected cells (Figure 3A). Among AA trea-
ted cells, PGD2 levels were increased by 40 or 105% in
Figure 1 Expression of H-rev107 and PTGDS in normal testis tissues. Mouse testis tissues were analyzed for expression of H-rev107 or
PTGDS by immunohistochemical staining using rabbit IgG, H-rev107, or PTGDS antibody. Arrows indicate positive H-rev107 and PTGDS staining
(magnification ×100, top panel; ×200, bottom panel) (A). Total cellular extracts from testis of mice were subjected to Western blot analysis for
H-rev107, PTGDS, and actin (B). Scale bar: 50 μm.
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Compared to the PTGDS-transfected cells, the levels of
PGD2 were furthered increased by 165% when cells co-
expressed PTGDS and H-rev107 (Figure 3A). In the
absence of exogenous AA addition, PGD2 levels were
increased by 59 or 124% in PTGDS- or H-rev107-
transfected cells, respectively (Figure 3B). Compared to
PTGDS–expressiong cells, PGD2 levels were enhanced
by 234% in PTGDS and H-rev107 co-transfected cells.
To dissect the effects of H-rev107 on PGD2 downstream
signalling molecules, we first measured the levels of
cAMP, a marker for the activation of PTGDS. NT2/D1
cells were transfected with PTGDS expression vector
along with H-rev107 or control vector. PGD2 profound-
ly increased intracellular cAMP by 42.9-fold in control
transfected NT2/D1 cells, slightly less than the effects of
the constitutive cAMP activator, Br-cAMP (Figure 3C).
Levels of cAMP production were increased by 11.6-fold
in PTGDS-expressing cells and were further increased
by 43.6-fold when the cells co-expressed PTGDS and
H-rev107. Expression of H-rev107 alone in NT2/D1
cells also enhanced cAMP levels by 31.2-fold. We alsoanalyzed the downstream signal followed by the activa-
tion of PTGDS using Western blotting as shown in our
previous study [36]. Levels of total SOX9 as well as the
phosphorylated (p-SOX9) proteins were increased by
3.4- and 8.3-fold, respectively, followed by H-rev107 ex-
pression in NT2/D1 cells (Figure 3D). These results re-
vealed that H-rev107 can enhance PTGDS activity in
NT2/D1 cells.
H-rev107 suppresses NT2/D1 cell migration and invasion
Expression of RIG1 in NT2/D1cells has been shown to
inhibit cell migration and invasion through the PGD2
signal pathway [36]. This study investigated the effect of
H-rev107 on cell migration and invasion in NT2/D1
cells. Numbers of migrated and invaded cells were de-
creased by 84.4% and 84.7%, respectively followed by
PGD2 treatment (Figure 4). Similarly, expression of
H-rev107 decreased the numbers of migrating or inva-
ded cells by 42.5% or 59%, respectively. The effect of
H-rev107 on cell viability and cell death were also inves-
tigated by the WST-1 and LDH assay, respectively, on
H-rev107 and control transfected NT2/D1 cells, and no
Figure 2 H-rev107 associates and co-localizes with PTGDS. Mouse TM4 cells plated in a 10-cm dish were transfected with 3 μg PTGDS-Flag
along with H-rev107-myc or the control vector for 24 h. Cell lysates were prepared as described in the Methods. The interaction between
H-rev107 and PTGDS was analyzed by immunoprecipitation followed by Western blot analysis. Immunoprecipitates were resolved by SDS-PAGE
and immunoblotted using anti-Flag antibody or anti-myc antibody (A). TM4 cells were transfected with EGFP-PTGDS or DsRED-H-rev107
expression vector alone or co-transfected with both vectors for 18 h. Cells were fixed, stained with DAPI, and analyzed with a laser scanning
confocal microscope (B). LC: light chain; scale bar: 10 μm.
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cated that H-rev107 and RIG1 exhibited similar inhibi-
tory effects on cell migration and invasion in NT2/D1
teratocarcinoma cells.
PGD2, cAMP, and SOX9 induction by H-rev107 was
mediated through PTGDS
Given that H-rev107 can induce PTGDS activity in
NT2/D1 cells, we investigated whether PTGDS is essen-
tial for the H-rev107-mediated PGD2 signal pathway.
We first silenced PTGDS and SOX9 expression and
then examined the production of PGD2 and cAMP in
H-rev107-expressing NT2/D1 cells. Levels of PTGDS
and SOX9 proteins were effectively downregulated by
the transduction of specific shRNAs (Figure 5C). Levels
of PGD2 and cAMP were increased by 3.4- and 3.2-fold
respectively in LacZ-transduced and H-rev107-expressed
cells. Among H-rev107 transfected cells, silencing of
PTGDS decreased PGD2 production by 59.9% to 74.3%
(Figure 5A) and decreased cAMP levels by 69.9% to
70.8% (Figure 5B). No effect on the PGD2 or cAMP pro-
duction was observed in cells transduced with SOX9shRNA. Furthermore, levels of H-rev107-induced SOX9
expression were lower than that of LacZ-silencing
cells when cells were transduced with PTGDS shRNA
(Figure 5C). The results suggest that H-rev107 stimu-
lates PGD2 production and downstream signals by
enhancing PTGDS activity.
H-rev107 suppresses cell migration and invasion through
PTGDS
Having found that expression of H-rev107 will increase
PGD2 production by modulating PTGDS activity, we
then determined the role of PTGDS and SOX9 in
H-rev107-mediated suppression of cell migration and in-
vasion. H-rev107 suppressed cell migration and invasion
by 79.1% and 73.4% respectively in the NT2/D1 cells
transduced with LacZ shRNA (Figure 6). In contrast, si-
lencing of PTGDS in NT2/D1 cells increased cell migra-
tion by 49% to 50.6%, and cell invasion by 40.6% to
47.5% in H-rev107 transfected cells. Similarly, silencing
of SOX9 in NT2/D1 cells reversed the H-rev107-medi-
ated suppression of cell migration by 42.3% to 44.6% and
cell invasion by 35.5% to 37.5% (Figure 6). Both PTGDS
Figure 4 H-rev107 suppresses cell migration and invasion. NT2/D1 cells plated in triplicate in 24-well plates were transfected with 500 ng of
H-rev107 or control expression vector and then incubated with 500 ng/mL of PGD2 or ethanol vehicle for 24 h. Cells were washed with serum
free medium and were seeded in triplicate in polycarbonate membrane inserts in 24-well plates. Lower wells containing 700 μL DMEM
supplemented with 20% FBS was served as chemoattractant. Migratory cells were stained after 24 h of incubation (A). Invasive activity was
measured using the Matrigel invasion assay after 72 h of incubation in serum containing medium supplemented with PGD2 or ethanol vehicle
(B). Representative results of three independent experiments are shown. Ctrl: control; Student’s t-test: *, P < 0.05; ***, P < 0.001.
Figure 3 H-rev107 increases PGD2 and cAMP levels and enhances the expression of SOX9 protein. NT2/D1 cells plated in triplicate in
6-well plates were transfected with 1 μg of indicated expression or control vector for 24 h. Cells were washed and then incubated with 1 μg/mL
AA for 1 h (A). Alternatively, cells were transfected with indicated expression or control vector and then incubated for 18 h in the presence of
1 mM Br-cAMP or ethanol vehicle for 18 h or 500 ng/mL PGD2 for 30 min as described in the Methods. Cell lysates were prepared, and levels of
PGD2 (A, B) or cAMP (C) were measured using an enzyme immunoassay. Representative results from triplicate samples were expressed as mean ± SD.
Student’s t-test: **, P <0.01; ***, P < 0.001. Cells were transfected with H-rev107 expression or control vector for 24 h. Expression of SOX9 and
phosphorylated SOX9 in total cellular extracts was determined by Western blot analysis (D).
Shyu et al. Journal of Biomedical Science 2013, 20:30 Page 7 of 12
http://www.jbiomedsci.com/content/20/1/30
Figure 5 PTGDS shRNAs prevent H-rev107-mediated enhancement of PGD2, cAMP, and SOX9 levels. NT2/D1 cells were transduced
with indicated shRNA for 72 h and then transfected with H-rev107 expression or control vector for 24 h. Levels of PGD2 (A) and cAMP (B) were
determined using enzyme immunoassays, and expression of SOX9 was determined by Western blot analysis using anti-SOX9 antibody (C).
Representative results from triplicate samples were expressed as means ± SD. Student’s t-test: **, P < 0.01; ***, P < 0.001.
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diated inhibition of cell migration and invasion in NT2/
D1 cells (Additional file 2: Figure S2).
H-rev107 suppresses Rac1 activation and increases E-
cadherin expression
The conversion of an epithelial cell to a mesenchymal
cell is necessary for cell migration and invasion [37,38].
We next examined the effects of H-rev107 on the activa-
tion of cellular Rac1 and the expression of E-cadherin
and vimentin. EGF stimulated Rac1-GTP levels by 14.3-
fold in NT2/D1 cells (Figure 7A). Compared to the
control transfected cells, the levels of EGF-stimulated
Rac1-GTP were suppressed by 62.6 and 21.9% in PGD2-
treated or H-rev107-transfected cells, respectively. In
addition, PGD2 treatment or H-rev107 transfection in-
creased E-cadherin levels by 1.7-1.9 fold (Figure 7B).
Vimentin expression was downregulated to 20% only in
H-rev107-transfected cells. PGD2 had no effect on vi-
mentin expression. We also analyzed the effect of PGD2
and H-rev107 on matrix metallopeptidase (MMP) activa-
tion. However, no change in the activity of MMP-9 or
MMP-2 was observed in NT2/D1 cells treated withPGD2 or transfected with H-rev107 expression vector
(data not shown).
Discussion
Based on the results from the present and our previous
[36] studies, both RIG1 and H-rev107 can interact with
PTGDS in testis cells. The interaction enhances PTGDS
activity, which increases PGD2 levels, elevates or acti-
vates downstream PGD2 signaling molecules like cAMP
and phosphorylated SOX9, and suppresses cell migration
and invasion. Both PTGDS and SOX9 shRNAs profoundly
alleviated RIG1-, H-rev107-, and PGD2-mediated inhi-
bition of cell migration and invasion. Therefore, the me-
chanism by which HREV107 family proteins attenuate the
migration and invasion of NT2/D1 cells is primarily medi-
ated through the activation of PTGDS and the production
of PGD2.
PGD2 has been shown to inhibit cell migration and in-
vasion. PGD2 inhibits the migration of airway dendric
cells and epidermal Langerhans cells to the draining
lymph nodes, and the inhibition is mediated through pros-
tanoid receptor 1 [39,40]. Similar inhibition of cell migra-
tion by PGD2 is also observed in eosinophils, basophils
Figure 6 PTGDS and SOX9 shRNA alleviates H-rev107-mediated
suppression of cell migration and invasion. NT2/D1 cells were
transduced with indicated shRNA for 72 h and then transfected with
H-rev107 expression vector for 24 h. Cells were then prepared for
analysis of cell migration (A) and invasion (B). Representative results
of three independent experiments are shown. Student’s t-test: ***,
P < 0.001 versus control; #, P <0.01; ##, P <0.001 versus H-rev107-
expressing cells that transduced with shLacZ.
Figure 7 H-rev107 suppresses Rac1 activation and increases
E-cadherin expression. NT2/D1 cells grown to 80% confluence
were transfected with the indicated control or H-rev107 expression
vector and then incubated with 500 ng/mL of PGD2 or ethanol
vehicle for 24 h. Cells were serum starved for 12 h and then stimulated
by EGF (50 ng/mL) for 5 min. Cellular lysates were incubated with
agarose conjugated with PAK-1 PBD. After washing, the bound
activated Rac1 (Rac1-GTP) was analyzed by Western blotting (A).
NT2/D1 cells were transfected with H-rev107 or control expression
vector and then incubated with 500 ng/mL of PGD2 or ethanol vehicle
for 24 h. The levels of E-cadherin and vimentin were determined by
Western blot analysis (B).
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whereas PGE2 stimulated invasion of PC-3 prostate can-
cer cells [43]. Also, PGD2 levels in primary colorectal car-
cinoma tissues without liver metastasis are shown to be
significantly lower than that with hepatic metastasis [44].
The results agree with the inhibition of cell migration and
invasion in NT2/D1 testis cancer cells followed by PGD2
treatment or the ectopic expression of RIG1 or H-rev107
shown in this and our previous studies [36]. Epithelial-
mesenchymal transition and elevated Rac activities havecritical roles in cellular motility and migration. PGD2 is
shown to inhibit TGF-β1-induced epithelial-mesenchymal
transition by increasing E-cadherin in MDCK cells [45].
Similarly, an increase in expression of E-cadherin and a
decrease in expression of mesenchymal marker protein
vimentin and in Rac 1 activation were observed in NT2/
D1 cells that expressed H-rev107. These results confirmed
the invasion-suppression capacity of H-rev107 in testes
cells. SOX9 is shown to be required in migration and
in invasion of uroepithelial carcinoma cells in vitro [34],
and upregulation of SOX9 is related to the progression
of prostate and gastric cancers [33-35]. However, we
observed that knockdown of PTGDS or SOX9 expression
effectively alleviated both RIG1 [36] and H-rev107-medi-
ated inhibition of cell migration and invasion in testis
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cell migration and invasion might be attributable to the
tissue specific effects of the protein.
The PGD2-SOX9 signal pathway is important in tes-
tis development [26]. PDG2 induces nuclear import of
SOX9 that subsequently induces Sertoli cell differen-
tiation [26]. The facts that the increase in PGD2 produc-
tion and SOX9 expression through PTGDS activation in
H-rev107 and RIG1 transfected NT2/D1 cells shown in
this and our previous [36] studies support pro-differenti-
ation activities of both RIG1 and H-rev107 in testis can-
cer cells. This is consistent with the finding that only
terminal differentiated testis tissues appear to contain
murine H-rev107, human HREV107 [17] and PTGDS.
Results from this and our previous [36] studies de-
monstrated similar biological activities between RIG1
and H-rev107 in the activation of PTGDS that subse-
quently increase the level of PGD2 and SOX9 and in-
hibit cell migration and invasion. Whether the activities
described above differ in potency between RIG1 and H-
rev107 remains unclear. A side-by-side comparison of
RIG1 and H-rev107 expression and downstream signa-
ling pathways will clarify the roles of RIG1 and H-rev107
in testes differentiation and in the inhibition of testis cell
invasion.
Previous studies have shown that the HREV107 family
proteins exhibit tumor suppressor activities in combi-
nation with various target proteins. In cervical cancer,
RIG1 suppresses cell growth and induces cell death
through caspase-dependent and -independent pathways
[12,24]. In skin cancer, RIG1 induces cell apoptosis by
promoting pericentrosomal organelle accumulation, which
is associated with the decrease in cyclin D1, cyclin E, and
Bcl-XL and the increase in p21 and Bax levels [22,46]. In
addition, both RIG1 and H-REV107 have been suggested
to exhibit phospholipase A(1/2) activity [3,5], which is
involved in H-rev107-mediated HEK cell death by regu-
lating peroxisomal lipid metabolism [47]. However, pro-
apoptotic activity of H-REV107 has not been observed in
testis cells. The use of phospholipase A(1/2) inhibitor can-
not alleviate the RIG1-mediated suppression of cell inva-
sion [36]. These results reveal that the targeted effects for
the HREV107 family proteins vary by cell type.
Aside from the difference in targeted proteins for
H-REV107, subcellular localization of H-REV107 would
be considered as an important factor that might have
impact on cell function. Nuclear targeted H-REV107
has been shown to stimulate cell growth of non-small
cell lung carcinomas [48]. In contrast, nuclear targeted
H-REV107111–123 and RIG1111–123 peptides induce pro-
found proapoptotic activities in cancer cells [12,49]. Re-
sults from most studies have revealed that the HREV107
family proteins are expressed in the perinuclear region
[6,13,14,23,24]. Perinuclear localization of RIG1 has beenshown to inhibit expression or activation of signaling
molecules such as HER2, RAS, PI3K/AKT, mTOR, and
type I transglutaminase that are involved in the re-
gulation of cell growth, apoptosis, tumor invasion, and
cell differentiation [11-13,24,50]. The downstream signal
transduction pathways involved in RIG1-mediated cell
function are dependent on the cell type and the binding
effectors. For example, the transglutaminase inhibitor
monodansylcadaverine can suppress RIG1-mediated ter-
minal differentiation of keratinocytes [23]. However, the
compound is not able to inhibit RIG1-mediated RAS
suppression and induce cell death of cervical cancer cells
(data not shown).
Results from this and our previous studies [36] sup-
port the roles of RIG1/H-rev107 in testis cell invasion/
migration. However, a signal cascade involving RIG1/
H-rev107-PTGDS-SOX9 has also been implicated in
testis development and differentiation based on results
from this and previous [17,26] studies. Due to the lack
of sex-differentiation marker like Mullerian hormone
and Sertoli cell marker [25] in cell line culture, an organ
culture of testis with Sertoli cells that support sper-
matogenesis at various stages of cell differentiation
will be used in our future studies. Also, analysis of
H-rev107 in the sex-determining cascade in ex vivo
using H-rev107 knockout mice will be helpful in iden-
tifying the signal responsible for H-rev107-mediated testis
development.Conclusions
In conclusion, H-rev107 and PTGDS are both highly
expressed in differentiated spermatids in normal testis
tissues. H-rev107 exhibited invasion-suppressive activity
in testis cancer cells. PTGDS is essential for H-rev107
-mediated production of PGD2, cAMP, and SOX9. Fur-
thermore, reduction of PTGDS or SOX9 alleviates the
H-rev107 mediated suppression of cell migration and in-
vasion. Further analysis of H-rev107 in gene knockout
mice will be useful to pinpoint the role of H-rev107 in
testis development.Additional files
Additional file 1: Figure S1. TM4 cells were co-transfected with
EGFP-PTGDS and DsRED-H-rev107 expression vector for 18 h. Cells were
fixed, stained with DAPI, and analyzed with a laser scanning confocal
microscope. Scale bar: 10 μm.
Additional file 2: Figure S2. PTGDS and SOX9 shRNAs alleviate
PGD2-mediated suppression of cell migration and invasion. NT2/D1 cells
were transduced with indicated shRNA for 72 h and then incubated with
500 ng/mL of PGD2 or ethanol vehicle for 24 h. Cells were subsequently
prepared for analysis of cell migration (A) and invasion (B). Representative
results of three independent experiments are shown. Student’s t-test: **,
P < 0.01 versus control; #, P <0.01; ##, P <0.001 versus PGD2-treated cells that
transduced with shLacZ.
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